These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17414649)

  • 1. The sympathetic nervous system and the metabolic syndrome.
    Mancia G; Bousquet P; Elghozi JL; Esler M; Grassi G; Julius S; Reid J; Van Zwieten PA
    J Hypertens; 2007 May; 25(5):909-20. PubMed ID: 17414649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome.
    Quarti Trevano F; Seravalle G; Macchiarulo M; Villa P; Valena C; Dell'Oro R; Mancia G; Grassi G
    J Hypertens; 2017 Aug; 35(8):1685-1690. PubMed ID: 28350577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives.
    Grassi G
    Hypertension; 2009 Oct; 54(4):690-7. PubMed ID: 19720958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome.
    Grassi G; Quarti-Trevano F; Seravalle G; Dell'Oro R
    Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):473-81. PubMed ID: 17451923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central sympathetic nervous system in hypertension.
    Mancia G; Grassi G
    Handb Clin Neurol; 2013; 117():329-35. PubMed ID: 24095136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers.
    Grassi G; Quarti-Trevano F; Seravalle G; Dell'Oro R; Facchetti R; Mancia G
    Hypertension; 2020 Aug; 76(2):577-582. PubMed ID: 32594806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sympathetic nervous system alterations in human hypertension.
    Grassi G; Mark A; Esler M
    Circ Res; 2015 Mar; 116(6):976-90. PubMed ID: 25767284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW
    Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP
    Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies.
    Quarti Trevano F; Dell'Oro R; Biffi A; Seravalle G; Corrao G; Mancia G; Grassi G
    J Hypertens; 2020 Apr; 38(4):565-572. PubMed ID: 32132429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.
    Thorp AA; Schlaich MP
    J Diabetes Res; 2015; 2015():341583. PubMed ID: 26064978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome.
    Grassi G
    Hypertens Res; 2006 Nov; 29(11):839-47. PubMed ID: 17345783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 'neuroadrenergic hypothesis' in hypertension: current evidence.
    Grassi G; Seravalle G; Quarti-Trevano F
    Exp Physiol; 2010 May; 95(5):581-6. PubMed ID: 20008032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and the sympathetic nervous system.
    Egan BM
    Curr Hypertens Rep; 2003 Jun; 5(3):247-54. PubMed ID: 12724058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome?
    Hausberg M; Barenbrock M; Kosch M
    J Hypertens; 2004 Jun; 22(6):1087-9. PubMed ID: 15167440
    [No Abstract]   [Full Text] [Related]  

  • 16. The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal denervation.
    Grassi G; Seravalle G; Brambilla G; Mancia G
    Can J Cardiol; 2012 May; 28(3):311-7. PubMed ID: 22244774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease.
    Patel SB; Reams GP; Spear RM; Freeman RH; Villarreal D
    Curr Hypertens Rep; 2008 Apr; 10(2):131-7. PubMed ID: 18474180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome.
    Grassi G; Arenare F; Quarti-Trevano F; Seravalle G; Mancia G
    Prog Cardiovasc Dis; 2009; 52(1):31-7. PubMed ID: 19615491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].
    Mancia G; Seravalle G; Grassi G
    Ann Ital Med Int; 1997; 12(4):217-22. PubMed ID: 9773576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sympathetic Neural Overdrive in the Obese and Overweight State.
    Grassi G; Biffi A; Seravalle G; Trevano FQ; Dell'Oro R; Corrao G; Mancia G
    Hypertension; 2019 Aug; 74(2):349-358. PubMed ID: 31203727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.